Genital Diseases, Female  >>  cisplatin  >>  Phase 2
Welcome,         Profile    Billing    Logout  

63 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
cisplatin / Generic mfg.
NCT00003345: Cisplatin Plus Irinotecan in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer

Completed
2
35
US
cisplatin, irinotecan hydrochloride
Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI)
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
10/01
10/01
NCT00005051: Combination Chemotherapy in Treating Patients With Advanced Ovarian Epithelial Cancer

Completed
2
US
carboplatin, cisplatin, paclitaxel, topotecan hydrochloride
NYU Langone Health, National Cancer Institute (NCI)
Ovarian Cancer
03/03
 
NCT00003369: S9717 Tirapazamine Plus Cisplatin in Treating Patients With Metastatic, Recurrent, or Refractory Cervical Cancer

Completed
2
56
US
cisplatin, platinol, tirapazamine
Southwest Oncology Group, National Cancer Institute (NCI)
Cervical Cancer
10/03
07/04
NCT00003624: Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer

Terminated
2
US
amifostine trihydrate, cisplatin, paclitaxel
Gynecologic Oncology Group, National Cancer Institute (NCI)
Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Neurotoxicity, Ovarian Cancer, Primary Peritoneal Cavity Cancer, Sarcoma
01/04
 
NCT00006942: Bryostatin 1 and Cisplatin in Treating Patients With Advanced Recurrent or Residual Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Completed
2
32
US
bryostatin 1, B705008K112, BRYO, Bryostatin, cisplatin, CACP, CDDP, CPDD, DDP, laboratory biomarker analysis
National Cancer Institute (NCI)
Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
03/04
 
NCT00005965: Bryostatin-1 Plus Cisplatin in Treating Patients With Recurrent or Advanced Cancer of the Cervix

Completed
2
US
bryostatin 1, cisplatin
Icahn School of Medicine at Mount Sinai, National Cancer Institute (NCI)
Cervical Cancer
 
04/04
NCT00002813: Combination Chemotherapy in Treating Patients With Recurrent or Refractory Cervical Cancer

Completed
2
62
US
cisplatin, vinorelbine tartrate
Gynecologic Oncology Group, National Cancer Institute (NCI)
Cervical Cancer
10/04
 
NCT00505492: Malignant Mixed Mesodermal Tumor (MMMT) - Early Stage With Postoperative XRT/Chemotherapy

Terminated
2
4
US
Carboplatin, paraplatin, Cisplatin, Platinol-AQ, Platinol, CDDP, Paclitaxel, Taxol
M.D. Anderson Cancer Center
Uterine Neoplasms
02/06
12/10
NCT00006482: Gemcitabine and Cisplatin in Treating Patients With Refractory or Recurrent Cancer of the Cervix

Terminated
2
US, Canada
cisplatin, gemcitabine hydrochloride
Gynecologic Oncology Group, National Cancer Institute (NCI)
Cervical Cancer
04/06
 
NCT00052312: Doxorubicin and Cisplatin With or Without Paclitaxel in Treating Patients With Locally Advanced, Metastatic, and/or Relapsed Endometrial Cancer

Completed
2
141
Europe
cisplatin, doxorubicin hydrochloride, paclitaxel
European Organisation for Research and Treatment of Cancer - EORTC
Endometrial Cancer
09/06
 
NCT00276796: Paclitaxel, Topotecan, and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer

Completed
2
66
US
cisplatin, paclitaxel, topotecan hydrochloride
Gynecologic Oncology Group, National Cancer Institute (NCI)
Cervical Cancer
01/07
 
NCT00006028: Gemcitabine Plus Cisplatin in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Is Recurrent or Has Not Responded to Platinum-based Chemotherapy

Completed
2
US, Europe
cisplatin, gemcitabine hydrochloride
Gynecologic Oncology Group, National Cancer Institute (NCI)
Ovarian Cancer, Primary Peritoneal Cavity Cancer
01/07
 
NCT00081276: 3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer

Completed
2
48
US
triapine, 3-AP, OCX-191, cisplatin, CACP, CDDP, CPDD, DDP, laboratory biomarker analysis
National Cancer Institute (NCI)
Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
01/07
 
NCT00314678: Cisplatin Induction With Paclitaxel Consolidation for Stage III-IV Epithelial Ovarian and Primary Peritoneal Cancer

Completed
2
40
US
Topotecan, Cisplatin, Paclitaxel
John P. Fruehauf, GlaxoSmithKline
Epithelial Ovarian Cancer, Primary Peritoneal Cancer
 
04/07
ERBUS, NCT00518193: Phase II Study , Association of Cisplatine Topotecan and Cetuximab in Patients Whith Late or in Progress Epithelial Cancer of the Cervix

Terminated
2
44
Europe
ERBITUX
ARCAGY/ GINECO GROUP
Cervix Cancer
07/07
09/08
NCT00001426: A Multi-Institutional Phase II Study of Cyclophosphamide, Paclitaxel, Cisplatin With G-CSF for Patients With Newly Diagnosed Advanced Stage Ovarian Cancer

Completed
2
66
US
Cyclophosphamide, Paclitaxel, Cisplatin, G-CSF
National Cancer Institute (NCI)
Ovarian Neoplasm
10/07
11/13
NCT00191334: Gemcitabine in Ovarian Cancer

Completed
2
50
RoW
gemcitabine, LY188011, Gemzar, cisplatin
Eli Lilly and Company
Ovarian Cancer
12/07
12/07
GEMCOL, NCT00421096: Radiochemotherapy Followed by Adjuvant Chemotherapy Based on Gemcitabine in Uterine Cervical Cancer

Terminated
2
19
Europe
Gemcitabine, Radiotherapy, Cisplatin
Centre Oscar Lambret
Uterine Cervical Cancer
04/08
12/11
NCT00136955: Irinotecan Study For Cervical Cancer

Completed
2
41
RoW
Irinotecan
Pfizer
Uterine Cervical Neoplasms
05/08
05/08
Tax-Over, NCT00772863: Efficacy and Safety of Subsequent Cisplatin and Docetaxel in Ovarian Cancer

Completed
2
37
RoW
docetaxel and cisplatin
Sanofi
Ovarian Neoplasms
06/08
 
NCT00331760: Intensity-Modulated Radiation Therapy to the Pelvis With or Without Chemotherapy in Treating Patients With Endometrial Cancer or Cervical Cancer That Has Been Removed By Surgery

Completed
2
106
Canada, US
cisplatin, intensity-modulated radiation therapy
Radiation Therapy Oncology Group, National Cancer Institute (NCI), NRG Oncology
Cervical Cancer, Endometrial Cancer
02/09
12/16
NCT00369122: Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer

Checkmark P2 data
Feb 2012 - Feb 2012: P2 data
Completed
2
60
US, Canada
Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar FKB238, BEVACIZUMAB, LICENSE HOLDER UNSPECIFIED, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, External Beam Radiation Therapy, Definitive Radiation Therapy, EBRT, External Beam Radiotherapy, External Beam RT, external radiation, External Radiation Therapy, external-beam radiation, Internal Radiation Therapy, BRACHYTHERAPY, internal radiation, Internal Radiation Brachytherapy, Radiation Brachytherapy
National Cancer Institute (NCI), Radiation Therapy Oncology Group
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Stage IB Cervical Cancer AJCC v6 and v7, Stage IIA Cervical Cancer AJCC v7, Stage IIB Cervical Cancer AJCC v6 and v7, Stage III Cervical Cancer AJCC v6 and v7
06/10
12/16
NCT00083122: Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Completed
2
45
US
cisplatin, CACP, CDDP, CPDD, DDP, alvocidib, FLAVO, flavopiridol, HMR 1275, L-868275, cisplatin/flavopiridol
National Cancer Institute (NCI)
Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer, Stage IIIA Ovarian Epithelial Cancer, Stage IIIA Primary Peritoneal Cavity Cancer, Stage IIIB Ovarian Epithelial Cancer, Stage IIIB Primary Peritoneal Cavity Cancer, Stage IIIC Ovarian Epithelial Cancer, Stage IIIC Primary Peritoneal Cavity Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Primary Peritoneal Cavity Cancer
07/10
05/12
NCT00068406: Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Cancer of the Vulva

Completed
2
61
US
3-Dimensional Conformal Radiation Therapy, 3-dimensional radiation therapy, 3D CONFORMAL RADIATION THERAPY, 3D CRT, 3D-CRT, Conformal Therapy, Radiation Conformal Therapy, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Conventional Surgery
Gynecologic Oncology Group, National Cancer Institute (NCI)
Stage III Vulvar Cancer, Stage IVB Vulvar Cancer, Vulvar Squamous Cell Carcinoma
12/10
01/12
NCT00231842: Adjuvant Radiation Therapy With Ifosfamide in Patients With Mixed Mesodermal Tumors of the Uterus

Completed
2
30
US
Ifosfamide, Radiation Therapy, Pelvic RT, Radiation, Cisplatin
Montefiore Medical Center
Uterine Cancer
07/11
07/11
NCT00101192: Cetuximab and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer

Completed
2
76
US
cetuximab, cisplatin
Gynecologic Oncology Group, National Cancer Institute (NCI), Bristol-Myers Squibb
Cervical Cancer
07/11
 
NCT00941070: Triapine, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer or Vaginal Cancer

Completed
2
26
US
triapine, 3-AP, OCX-191, cisplatin, CACP, CDDP, CPDD, DDP, external beam radiation therapy, EBRT, quality-of-life assessment, quality of life assessment, questionnaire administration, fludeoxyglucose F 18, 18FDG, FDG, positron emission tomography, FDG-PET, PET, PET scan, tomography, emission computed, computed tomography, tomography, computed
National Cancer Institute (NCI)
Recurrent Cervical Cancer, Recurrent Vaginal Cancer, Stage IB Cervical Cancer, Stage II Vaginal Cancer, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage III Vaginal Cancer, Stage IVA Cervical Cancer, Stage IVA Vaginal Cancer, Stage IVB Cervical Cancer, Stage IVB Vaginal Cancer, Therapy-related Toxicity
04/12
07/12
NCT00950261: Efficacy Study for Postoperative Chemoradiation Using Triweekly Cisplatin in Cervical Cancer Patients

Withdrawn
2
0
RoW
tri-weekly cisplatin
Korea Cancer Center Hospital
Cervical Neoplasms
05/12
05/12
NCT01005329: Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer

Checkmark ASTRO 2013
Sep 2013 - Sep 2013: ASTRO 2013
Completed
2
34
US, Canada, RoW
Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar FKB238, BEVACIZUMAB, LICENSE HOLDER UNSPECIFIED, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Intensity-Modulated Radiation Therapy, IMRT, Intensity Modulated RT, Intensity-Modulated Radiotherapy, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat
National Cancer Institute (NCI), Radiation Therapy Oncology Group
Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Stage IA Uterine Corpus Cancer AJCC v7, Stage IB Uterine Corpus Cancer AJCC v7, Stage II Uterine Corpus Cancer AJCC v7, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Stage IVA Uterine Corpus Cancer AJCC v7, Stage IVB Uterine Corpus Cancer AJCC v7
06/12
09/13
NCT01200797: SJG-136 in Treating Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer That Did Not Respond to Previous Treatment With Cisplatin or Carboplatin

Terminated
2
19
US
SJG-136, laboratory biomarker analysis
National Cancer Institute (NCI)
Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer
10/12
02/13
NCT00548418: Topotecan, Cisplatin and Bevacizumab for Recurrent/Persistent Cervical Cancer

Completed
2
27
US
Topotecan, Hycamtin, Cisplatin, CDDP, Platin, Bevacizumab, Avastin
Washington University School of Medicine, GlaxoSmithKline, Genentech, Inc.
Cervical Cancer
12/12
12/12
NCT00590967: A Phase II Study of Extended Field IMRT External Beam Irradiation and Intracavitary Brachytherapy

Terminated
2
69
US
IMRT extended field external beam radiation therapy, Brachytherapy, Cisplatin
Washington University School of Medicine
Cervical Cancer
01/13
01/13
NCT02365935: 4 Versus 6 Courses of Adjuvant Chemotherapy in LACC Patients Previously Treated With NACT Plus Radical Surgery

Completed
2
215
Europe
Group A adjuvant chemotherapy, 4 cycles, Group B adjuvant chemotherapy, Cisplatin, Paclitaxel
Campus Bio-Medico University
Uterine Cervical Neoplasms
01/13
09/14
NCT01918124: A Phase II Trial of Adjuvant Radiotherapy Combined With Chemotherapy for Patients With High-risk Endometrial Cancer

Completed
2
80
RoW
radiotherapy, Cisplatin, Cisplatin and Doxorubicin and Cyclophosphamide, Paclitaxel and Carboplatin
Fan Ming
Prosthesis Survival
01/13
01/14
NCT00369954: Gemcitabine and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Responded to Previous Cisplatin or Carboplatin

Withdrawn
2
0
RoW
carboplatin, gemcitabine hydrochloride
Gynecologic Oncology Group, National Cancer Institute (NCI)
Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
 
 
NCT00388154: Gemcitabine and Cisplatin for Advanced or Recurrent Endometrial Cancer

Completed
2
21
US
Gemcitabine, Gemzar, Gemcitabine Hydrochloride, Cisplatin, Platinol-AQ, Platinol, CDDP
M.D. Anderson Cancer Center
Endometrial Cancer
11/13
11/13
NCT00957411 / 2008-001053-18: Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage IB, Stage II, or Stage IIIB Cervical Cancer

Checkmark TAT 2014
Mar 2014 - Mar 2014: TAT 2014
Completed
2
76
Europe
cetuximab, cisplatin
Institut Curie
Cervical Cancer
11/13
10/14
NCT00916500: Concurrent Chemoradiation With Cisplatin Every 3 Week in Advanced Cervical Cancer

Completed
2
71
RoW
CONCURRENT CHEMORADIATION (CISPLATIN), Cisplatin
Korea Cancer Center Hospital
CERVICAL NEOPLASMS
12/13
12/13
NCT01659554: A Phase II Combined Modality Protocol of Debulking Surgery With HIPEC Followed by Intraperitoneal Chemotherapy for the Treatment of Recurrent Ovarian, Primary Peritoneal & Fallopian Tube Cancers

Terminated
2
4
US
Cisplatin, cis-diamminedichloroplatinum(II) (CDDP), Platinol, Platinol-AQ, Doxorubicin, hydroxyldaunorubicin, Adriamycin
Columbia University
Recurrent Ovarian Cancer, Fallopian Tube Cancer
04/14
04/14
NCT01163552: Heated Chemotherapy for Cancers That Have Spread to the Chest Cavity

Completed
2
5
US
Surgical debulking and Intrathoracic Hyperthermic Chemotherapy
St. Luke's-Roosevelt Hospital Center
Pleural Metastases, Breast Cancer, Colon Cancer, Ovarian Cancer, Uterine Cancer, Renal Cell Cancer, Thymic Cancer
05/14
05/14
NCT00691301: Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer

Completed
2
55
US
cisplatin, pemetrexed disodium
Gynecologic Oncology Group, National Cancer Institute (NCI)
Cervical Cancer
07/14
07/14
NCT00588237: Intravenous and Intraperitoneal Paclitaxel, Intraperitoneal Cisplatin, and Intravenous Bevacizumab for the Initial Treatment of Optimal Stage II or III Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

Completed
2
42
US
Paclitaxel,Cisplatin, Bevacizumab
Memorial Sloan Kettering Cancer Center, Genentech, Inc.
Ovarian Cancer, Primary PERITONEUM, Fallopian Tube Cancer
11/14
11/14
NCT01276730: Advanced Cervical Cancer Trial in India

Completed
2
209
RoW
Interferon, Retinoic Acid and radiation, Cisplatin and radiation
University of Louisville, James Graham Brown Cancer Center
Cervical Cancer
08/15
08/15
NCT01936974: (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma

Terminated
2
7
US
Gemcitabine, Gemzar, Bevacizumab, Avastin, Carboplatin, Paraplatin, Cisplatin, Platinol, Oxaliplatin, Eloxatin
Western Regional Medical Center
Ovarian Carcinoma, Fallopian Tube Carcinoma, Peritoneal Carcinoma
08/15
08/15
NCT00511992: Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer

Completed
2
20
US
Avastin, Bevacizumab, Paclitaxel, Cisplatin
University of Oklahoma, Genentech, Inc.
Advanced Ovarian Carcinoma, Primary Peritoneal Carcinoma, Ovarian Carcinosarcoma
08/15
08/15
NCT01669226: First-line Intraperitoneal Cisplatin and Etoposide Chemotherapy for Ovarian Cancer

Completed
2
215
RoW
PEip (weekly) and TCiv, platinum, VP 16, taxane, TCiv
Shanghai Gynecologic Oncology Group, Fudan University, Shanghai Jiao Tong University School of Medicine, Shanghai Zhongshan Hospital
Bulky Stage IIIC and IV Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
09/15
07/16
NCT02309658: Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer Patients

Completed
2
50
RoW
gemcitabine, Gemzar and cisplatin neoadjuvant chemotherapy, cisplatin, chemoradiation
Professor Fernando Figueira Integral Medicine Institute, Instituto Nacional de Cancer, Brazil
Cancer of Cervix
10/15
10/15
NCT01867086: Salvage Ovarian FANG™ Vaccine + Carboplatinum

Completed
2
1
US
Vigil™ Vaccine, bi-shRNA furin and GMCSF Augmented Autologous Tumor Cell Vaccine, formerly known as FANG™, Carboplatinum, Carboplatinum and Taxol
Gradalis, Inc.
Stage III Ovarian Cancer, Stage IV Ovarian Cancer
04/16
04/16
NCT02501278: A Phase II Clinical Trial of Chemo-radiotherapy in Combination With INO-3112 in Patients With Locally Advanced Cervical Cancer

Withdrawn
2
0
Europe
INO-3112 vaccine, Radiotherapy (Extrernal beam radiotherapy + brachytherapy), Cisplatin chemotherapy
European Organisation for Research and Treatment of Cancer - EORTC, Inovio Pharmaceuticals, Centre Hospitalier Universitaire Vaudois
Uterine Cervical Neoplasms
05/19
05/21
NCT02432365: Study of Weekly Paclitaxel and Cisplatin in FIGO IB2 and IIA2 Cervical Cancer Followed by Radical Hysterectomy

Recruiting
2
64
RoW
paclitaxel, Taxol, cisplatin, Kemoplat, Radical hysterectomy and bilateral pelvic lymphadenectomy, RH-PLND
Chang Gung Memorial Hospital, Asian Gynecologic Oncology Group, Taiwanese Gynecologic Oncology Group
Cervical Cancer
12/23
12/23
NCT00023660: Radiation Therapy Plus Celecoxib, Fluorouracil, and Cisplatin in Patients With Locally Advanced Cervical Cancer

Completed
1/2
84
US
celecoxib, cisplatin, fluorouracil, brachytherapy, radiation therapy
Radiation Therapy Oncology Group, National Cancer Institute (NCI)
Cervical Cancer
01/05
 
NCT00003379: Radiation Therapy Plus Paclitaxel and Cisplatin in Treating Patients With Cervical Cancer

Completed
1/2
40
US
cisplatin, paclitaxel, brachytherapy, radiation therapy
Gynecologic Oncology Group, National Cancer Institute (NCI)
Cervical Cancer
01/07
 
NCT00012012: Radiation Therapy and Cisplatin With or Without Amifostine for Patients With Stage IIIB or IVA Cervical Cancer

Completed
1/2
45
US
Amifostine trihydrate, ethanethiol, Cisplatin, Intracavitary brachytherapy, External beam radiation therapy
Radiation Therapy Oncology Group, National Cancer Institute (NCI)
Cervical Cancer, Radiation Toxicity
09/07
06/10
NCT00091377: Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Completed
1/2
65
US, RoW
cisplatin, paclitaxel, phenoxodiol
MEI Pharma, Inc.
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
12/07
03/08
NCT00889733: Intraperitoneal (IP) Cisplatin Given With Paclitaxel to Treat Epithelial Ovarian Cancer

Terminated
1/2
9
Canada
Intraperitoneal (IP) Cisplatin
University Health Network, Toronto, Princess Margaret Hospital, Canada
Epithelial Ovarian Cancer
07/09
12/09
NCT00510250: A Phase I/II Study of Cisplatin and Radiation in Combination With Sorafenib in Cervical Cancer

Completed
1/2
13
Canada
Sorafenib, Cisplatin, Radiation
University Health Network, Toronto, Bayer
Cancer of the Cervix
09/10
07/15
NCT01076400 / 2009-017054-12: A Study of Adavosertib (MK-1775) in Combination With Topotecan/Cisplatin in Participants With Cervical Cancer (MK-1775-008)

Terminated
1/2
7
NA
adavosertib, MK-1775, Topotecan, Cisplatin, Placebo to adavosertib
Merck Sharp & Dohme LLC
Cervical Cancer
06/11
06/11
NCT01083537: Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer and Inoperable Malignant Bowel Obstruction

Terminated
1/2
1
Canada
Cisplatin, Paclitaxel
University Health Network, Toronto
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer, Bowel Obstruction
06/12
06/12
NCT02095119: A Monoclonal Antibody, Nimotuzumab, as Treatment for Recurrent or Metastatic Cervical Cancer

Completed
1/2
15
RoW
Nimotuzumab, Cisplatin, Gemcitabine, CT Scan
National Institute of Cancerología
Uterine Cervical Cancer
12/13
03/14
NCT01088347 / 2009-015941-22: Mapatumumab, Cisplatin and Radiotherapy for Advanced Cervical Cancer

Completed
1/2
9
Europe
mapatumumab, cisplatin, radiotherapy
University Medical Center Groningen, Human Genome Sciences Inc.
Advanced Cervical Cancer
03/14
03/14
NCT01709487: Feasibility Study of HIPEC for Patients With Stage III or Only Pleural Stage IV Ovarian Carcinoma in First Line Therapy

Completed
1/2
19
Europe
HIPEC
Jules Bordet Institute
Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
10/15
10/15
DEPICT, NCT01793701: Intensity-modulated Radiotherapy for Locally Advanced Cervical Cancer

Active, not recruiting
1/2
22
Europe
intensity modulated radiotherapy, IMRT, Intracavitary brachytherapy, Cisplatin
Queen Mary University of London, Barts & The London NHS Trust, Barts Cancer Institute
Locally Advanced Cervical Cancer
04/16
04/18
DEPICT, NCT01230996: Dose Escalation Study of Simultaneous Boost Intensity-Modulated Radiotherapy for Locally Advanced Cervical Cancer

Completed
1/2
22
Europe
Cisplatin, Intensity-modulated radiation therapy, IMRT, Intracavitary brachytherapy
Barts & The London NHS Trust
Locally Advanced Cervical Cancer
07/18
07/18

Download Options